Russell Investments Group Ltd. Has $1.37 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Russell Investments Group Ltd. lessened its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 40.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,415 shares of the company’s stock after selling 81,095 shares during the period. Russell Investments Group Ltd. owned approximately 0.12% of Intellia Therapeutics worth $1,369,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sit Investment Associates Inc. boosted its stake in shares of Intellia Therapeutics by 42.7% in the fourth quarter. Sit Investment Associates Inc. now owns 85,500 shares of the company’s stock valued at $997,000 after buying an additional 25,600 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Intellia Therapeutics by 38.3% during the 4th quarter. Wells Fargo & Company MN now owns 277,692 shares of the company’s stock worth $3,238,000 after purchasing an additional 76,872 shares in the last quarter. Resona Asset Management Co. Ltd. bought a new position in shares of Intellia Therapeutics in the fourth quarter worth $43,000. ExodusPoint Capital Management LP raised its stake in Intellia Therapeutics by 98.4% in the fourth quarter. ExodusPoint Capital Management LP now owns 105,827 shares of the company’s stock valued at $1,234,000 after purchasing an additional 52,486 shares in the last quarter. Finally, Arete Wealth Advisors LLC acquired a new stake in Intellia Therapeutics during the fourth quarter worth about $121,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock opened at $7.23 on Monday. The company has a 50-day simple moving average of $8.89 and a two-hundred day simple moving average of $12.11. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.18. The stock has a market capitalization of $748.43 million, a PE ratio of -1.33 and a beta of 2.23.

Analyst Ratings Changes

NTLA has been the subject of a number of recent analyst reports. Truist Financial cut their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Chardan Capital reduced their target price on Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a report on Friday, February 28th. HC Wainwright started coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price target for the company. Morgan Stanley cut Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $56.00 to $11.00 in a research report on Monday, January 27th. Finally, Wells Fargo & Company dropped their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.